Glycoconjugate vaccines against antimicrobial resistant pathogens

References

• Murray CJL, Ikuta KS, Sharara F, et al. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet. 2022;399(10325):629–655. doi: 10.1016/S0140-6736(21)02724-0
   PubMed Web of Science ®Google Scholar
• Micoli F, Bagnoli F, Rappuoli R, et al. The role of vaccines in combatting antimicrobial resistance. Nat Rev Microbiol. 2021 May;19(5):287–302. doi: 10.1038/s41579-020-00506-3
   PubMed Web of Science ®Google Scholar
• RAND E. How drug resistant infections are undermining modern medicine and why more research is needed now. London: Wellcome Trust; 2021.
   Google Scholar
• Tacconelli E, Carrara E, Savoldi A, et al. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis. 2018;18(3):318–327. doi: 10.1016/S1473-3099(17)30753-3
   PubMed Web of Science ®Google Scholar
• Vekemans J, Hasso-Agopsowicz M, Kang G, et al. Leveraging vaccines to reduce antibiotic use and prevent antimicrobial resistance: a World health organization action framework. Clin Infect Dis. 1017 [2021 Aug 16];73(4):e1011–e. doi: 10.1093/cid/ciab062
   PubMed Web of Science ®Google Scholar
• Ladhani SN, Collins S, Djennad A, et al. Rapid increase in non-vaccine serotypes causing invasive pneumococcal disease in England and wales, 2000-17: a prospective national observational cohort study. Lancet Infect Dis. 2018;18(4):441–451. doi: 10.1016/S1473-3099(18)30052-5
   PubMed Web of Science ®Google Scholar
• Chandler T, Furmanek S, Carrico R, et al. 23-Valent Pneumococcal Polysaccharide Vaccination Does Not Prevent Community-Acquired Pneumonia Hospitalizations Due to Vaccine-Type Streptococcus pneumoniae. Microorganisms. 2022 Mar 4;10(3):560. doi: 10.3390/microorganisms10030560
   PubMed Web of Science ®Google Scholar
• Hoelzer K, Bielke L, Blake DP, et al. Vaccines as alternatives to antibiotics for food producing animals. Part 1: challenges and needs. Vet Res. 2018 Jul 31;49(1):64. doi: 10.1186/s13567-018-0560-8
   PubMedGoogle Scholar
• Frost I, Sati H, Garcia-Vello P, et al. The role of bacterial vaccines in the fight against antimicrobial resistance: an analysis of the preclinical and clinical development pipeline. Lancet Microbe. 2022;4(2):e113–e125. doi: 10.1016/S2666-5247(22)00303-2
   PubMedGoogle Scholar
• Micoli F, Costantino P, Adamo R. Potential targets for next generation antimicrobial glycoconjugate vaccines. FEMS Microbiol Rev. 2018;42(3):388–423. doi: 10.1093/femsre/fuy011
   PubMed Web of Science ®Google Scholar
• Rappuoli R. Glycoconjugate vaccines: Principles and mechanisms. Sci Transl Med. 2018 Aug 29;10(456). doi: 10.1126/scitranslmed.aat4615
   PubMed Web of Science ®Google Scholar
• Stefanetti G, Borriello F, Richichi B, et al. Immunobiology of carbohydrates: implications for novel vaccine and adjuvant design against infectious diseases [review]. Front Cell Infect Microbiol. 2022 Jan 18;11:11.
   Web of Science ®Google Scholar
• Luong P, Dube DH. Dismantling the bacterial glycocalyx: chemical tools to probe, perturb, and image bacterial glycans. Bioorg Med Chem. 2021 Jul 15;42:116268. doi: 10.1016/j.bmc.2021.116268
   PubMed Web of Science ®Google Scholar
• Jha V, Janoff EN. Complementary role of CD4+ T cells in response to pneumococcal polysaccharide vaccines in humans. Vaccines (Basel). 2019 Feb 11;7(1):18. doi: 10.3390/vaccines7010018
   PubMed Web of Science ®Google Scholar
• Vos Q, Lees A, Wu ZQ, et al. B-cell activation by T-cell-independent type 2 antigens as an integral part of the humoral immune response to pathogenic microorganisms. Immunol Rev. 2000 Aug;176:154–170.
   PubMed Web of Science ®Google Scholar
• Craxton A, Magaletti D, Ryan EJ, et al. Macrophage- and dendritic cell–dependent regulation of human B-cell proliferation requires the TNF family ligand BAFF. Blood. 2003 Jun 1;101(11):4464–4471. doi: 10.1182/blood-2002-10-3123
   PubMed Web of Science ®Google Scholar
• Khatun F, Toth I, Stephenson RJ. Immunology of carbohydrate-based vaccines. Adv Drug Deliv Rev. 2020;165-166:117–126. doi: 10.1016/j.addr.2020.04.006
   PubMed Web of Science ®Google Scholar
• Snapper CM, Mond JJ. A model for induction of T cell-independent humoral immunity in response to polysaccharide antigens. J Immunol. 1996;157(6):2229–2233. doi: 10.4049/jimmunol.157.6.2229
   PubMed Web of Science ®Google Scholar
• Pace D. Glycoconjugate vaccines.Expert Opin Biol Ther. 2013 Jan 1;13(1):11–33. doi: 10.1517/14712598.2012.725718
   PubMed Web of Science ®Google Scholar
• Pishesha N, Harmand TJ, Ploegh HL. A guide to antigen processing and presentation. Nat Rev Immunol. 2022 Dec;22(12):751–764. doi: 10.1038/s41577-022-00707-2
   PubMed Web of Science ®Google Scholar
• Richmond P, Kaczmarski E, Borrow R, et al. Meningococcal C polysaccharide vaccine induces immunologic hyporesponsiveness in adults that is overcome by meningococcal C conjugate vaccine. J Infect Dis. 2000 Feb;181(2):761–764. doi: 10.1086/315284
   PubMed Web of Science ®Google Scholar
• Brynjolfsson SF, Henneken M, Bjarnarson SP, et al. Hyporesponsiveness following booster immunization with bacterial polysaccharides is caused by apoptosis of memory B cells. J Infect Dis. 2011;205(3):422–430. doi: 10.1093/infdis/jir750
   PubMed Web of Science ®Google Scholar
• Bjarnarson SP, Benonisson H, Del Giudice G, et al. Pneumococcal polysaccharide abrogates conjugate-induced germinal center reaction and depletes antibody secreting cell pool, causing hyporesponsiveness. PLoS One. 2013;8(9):e72588. doi: 10.1371/journal.pone.0072588
   PubMed Web of Science ®Google Scholar
• Zandvoort A, Timens W. The dual function of the splenic marginal zone: essential for initiation of anti-TI-2 responses but also vital in the general first-line defense against blood-borne antigens. Clin Exp Immunol. 2002 Oct;130(1):4–11. doi: 10.1046/j.1365-2249.2002.01953.x
   PubMed Web of Science ®Google Scholar
• Siegrist CA, Aspinall R. B-cell responses to vaccination at the extremes of age. Nat Rev Immunol. 2009 Mar;9(3):185–194. doi: 10.1038/nri2508
   PubMed Web of Science ®Google Scholar
• Sun L, Middleton DR, Wantuch PL, et al. Carbohydrates as T-cell antigens with implications in health and disease. Glycobiology. 2016 Oct;26(10):1029–1040. doi: 10.1093/glycob/cww062
   PubMed Web of Science ®Google Scholar
• Avci FY, Li X, Tsuji M, et al. A mechanism for glycoconjugate vaccine activation of the adaptive immune system and its implications for vaccine design. Nat Med. 2011 Nov 20;17(12):1602–1609. doi: 10.1038/nm.2535
   PubMed Web of Science ®Google Scholar
• Koj S, Lugowski C, Niedziela T. In-cell depolymerization of polysaccharide antigens. Exploring the processing pathways of glycans and why some glycoconjugate vaccines are less effective than expected: a review. Carbohydr Polym. 2023 Sep 1;315:120969. doi: 10.1016/j.carbpol.2023.120969
   PubMed Web of Science ®Google Scholar
• Micoli F, Stefanetti G, MacLennan CA. Exploring the variables influencing the immune response of traditional and innovative glycoconjugate vaccines [review]. Front Mol Biosci. 2023 May 16;10:10. doi: 10.3389/fmolb.2023.1201693
   Web of Science ®Google Scholar
• Middleton DR, Sun L, Paschall AV, et al. T Cell-Mediated Humoral Immune Responses to type 3 capsular polysaccharide of streptococcus pneumoniae. J Immunol. 2017 Jul 15;199(2):598–603. doi: 10.4049/jimmunol.1700026
   PubMed Web of Science ®Google Scholar
• Sun X, Stefanetti G, Berti F, et al. Polysaccharide structure dictates mechanism of adaptive immune response to glycoconjugate vaccines. Proc Natl Acad Sci, USA. 2019 Jan 2;116(1):193–198. doi: 10.1073/pnas.1816401115
   PubMed Web of Science ®Google Scholar
• Romano MR, Berti F, Rappuoli R. Classical- and bioconjugate vaccines: comparison of the structural properties and immunological response. Curr Opin Immunol. 2022 Oct 01;78:102235. doi: 10.1016/j.coi.2022.102235
   PubMed Web of Science ®Google Scholar
• Del Bino L, Østerlid KE, Wu D-Y, et al. Synthetic glycans to improve Current glycoconjugate vaccines and fight antimicrobial resistance. Chem Rev. 2022 Oct 26;122(20):15672–15716. doi: 10.1021/acs.chemrev.2c00021
   PubMed Web of Science ®Google Scholar
• Micoli F, Del Bino L, Alfini R, et al. Glycoconjugate vaccines: current approaches towards faster vaccine design. Expert Rev Vaccines. 2019 Sep 2;18(9):881–895. doi: 10.1080/14760584.2019.1657012
   PubMed Web of Science ®Google Scholar
• Verez-Bencomo V, Fernández-Santana V, Hardy E, et al. A synthetic conjugate polysaccharide vaccine against haemophilus influenzae type b. Science. 2004 Jul 23;305(5683):522–525. doi: 10.1126/science.1095209
   PubMed Web of Science ®Google Scholar
• Cohen D, Atsmon J, Artaud C, et al. Safety and immunogenicity of a synthetic carbohydrate conjugate vaccine against shigella flexneri 2a in healthy adult volunteers: a phase 1, dose-escalating, single-blind, randomised, placebo-controlled study. Lancet Infect Dis. 2021 Apr;21(4):546–558. doi: 10.1016/S1473-3099(20)30488-6
   PubMed Web of Science ®Google Scholar
• Seeberger PH. Discovery of semi- and fully-synthetic carbohydrate vaccines against bacterial infections using a medicinal chemistry approach.Chem Rev. 2021;121(7):3598–3626. doi: 10.1021/acs.chemrev.0c01210
   PubMed Web of Science ®Google Scholar
• Fiebig T, Freiberger F, Pinto V, et al. Molecular cloning and functional characterization of components of the capsule biosynthesis complex of Neisseria meningitidis serogroup A: toward in vitro vaccine production. J Biol Chem. 2014;289(28):19395–19407. doi: 10.1074/jbc.M114.575142
   PubMed Web of Science ®Google Scholar
• Fiebig T, Romano MR, Oldrini D, et al. An efficient cell free enzyme-based total synthesis of a meningococcal vaccine candidate. NPJ Vaccines. 2016;1(1):16017. doi: 10.1038/npjvaccines.2016.17
   PubMedGoogle Scholar
• Oldrini D, Fiebig T, Romano MR, et al. Combined chemical synthesis and tailored enzymatic elongation provide fully synthetic and conjugation-ready Neisseria meningitidis serogroup X vaccine antigens. ACS Chem Biol. 2018 Apr 20;13(4):984–994. doi: 10.1021/acschembio.7b01057
   PubMed Web of Science ®Google Scholar
• Berti F, Adamo R. Antimicrobial glycoconjugate vaccines: an overview of classic and modern approaches for protein modification [10.1039/C8CS00495A]. Chem Soc Rev. 2018;47(24):9015–9025. doi: 10.1039/C8CS00495A
   PubMed Web of Science ®Google Scholar
• Kapoor N, Vanjak I, Rozzelle J, et al. Malaria derived glycosylphosphatidylinositol anchor enhances anti-Pfs25 functional antibodies that block malaria transmission. Biochem. 2018;57(5):516–519. doi: 10.1021/acs.biochem.7b01099
   PubMed Web of Science ®Google Scholar
• Kapoor N, Uchiyama S, Pill L, et al. Non-native amino acid click chemistry-based technology for site-specific polysaccharide conjugation to a bacterial protein serving as both carrier and vaccine antigen. ACS Omega. 2022 Jul 19;7(28):24111–24120. doi: 10.1021/acsomega.1c07360
   PubMed Web of Science ®Google Scholar
• Fairman J, Agarwal P, Barbanel S, et al. Non-clinical immunological comparison of a next-generation 24-valent pneumococcal conjugate vaccine (VAX-24) using site-specific carrier protein conjugation to the current standard of care (PCV13 and PPV23). Vaccine. 2021 May 27;39(23):3197–3206. doi: 10.1016/j.vaccine.2021.03.070
   PubMed Web of Science ®Google Scholar
• Dow JM, Mauri M, Scott TA, et al. Improving protein glycan coupling technology (PGCT) for glycoconjugate vaccine production. Expert Rev Vaccines. 2020 June 2;19(6):507–527. doi: 10.1080/14760584.2020.1775077
   PubMed Web of Science ®Google Scholar
• Wacker M, Linton D, Hitchen PG, et al. N-linked glycosylation in Campylobacter jejuni and its functional transfer into E. coli. Science. 2002 Nov 29;298(5599):1790–1793. doi: 10.1126/science.298.5599.1790
   PubMed Web of Science ®Google Scholar
• Kay E, Cuccui J, Wren BW. Recent advances in the production of recombinant glycoconjugate vaccines.NPJ Vaccines. 2019 May 1;4(1):16. doi: 10.1038/s41541-019-0110-z
   PubMed Web of Science ®Google Scholar
• Kowarik M, Young NM, Numao S, et al. Definition of the bacterial N-glycosylation site consensus sequence. EMBO J. 2006 May 3;25(9):1957–1966. doi: 10.1038/sj.emboj.7601087
   PubMed Web of Science ®Google Scholar
• Kowarik M, Wetter M, Haeuptle MA, et al. The development and characterization of an E. coli O25B bioconjugate vaccine. Glycoconj J. 2021 Aug;38(4):421–435. doi: 10.1007/s10719-021-09985-9
   PubMed Web of Science ®Google Scholar
• Herbert JA, Kay EJ, Faustini SE, et al. Production and efficacy of a low-cost recombinant pneumococcal protein polysaccharide conjugate vaccine. Vaccine. 2018 Jun 18;36(26):3809–3819. doi: 10.1016/j.vaccine.2018.05.036
   PubMed Web of Science ®Google Scholar
• Harding CM, Feldman MF. Glycoengineering bioconjugate vaccines, therapeutics, and diagnostics in E. coli. Glycobiology. 2019 Jul 1;29(7):519–529. doi: 10.1093/glycob/cwz031
   PubMed Web of Science ®Google Scholar
• Riddle MS, Kaminski RW, Di Paolo C, et al. Safety and immunogenicity of a candidate bioconjugate vaccine against shigella flexneri 2a administered to healthy adults: a single-blind, randomized phase I study. Clin Vaccine Immunol. 2016 Dec;23(12):908–917. doi: 10.1128/CVI.00224-16
   PubMed Web of Science ®Google Scholar
• Talaat KR, Alaimo C, Martin P, et al. Human challenge study with a shigella bioconjugate vaccine: analyses of clinical efficacy and correlate of protection. EBioMedicine. 2021;66:66. doi: 10.1016/j.ebiom.2021.103310
   Web of Science ®Google Scholar
• Saade E, Gravenstein S, Donskey CJ, et al. Characterization of Escherichia coli isolates potentially covered by ExPEC4V and ExPEC10V, that were collected from post-transrectal ultrasound-guided prostate needle biopsy invasive urinary tract and bloodstream infections. Vaccine. 2020 Jul 14;38(33):5100–5104. doi: 10.1016/j.vaccine.2020.06.024
   PubMed Web of Science ®Google Scholar
• Scully IL, Timofeyeva Y, Illenberger A, et al. Performance of a Four-Antigen Staphylococcus aureus vaccine in preclinical models of invasive S. aureus disease. Microorganisms. 2021 Jan 15;9(1):177. doi: 10.3390/microorganisms9010177
   PubMed Web of Science ®Google Scholar
• Gurtman A, Begier E, Mohamed N, et al. The development of a staphylococcus aureus four antigen vaccine for use prior to elective orthopedic surgery. Hum Vaccin Immunother. 2019;15(2):358–370. doi: 10.1080/21645515.2018.1523093
   PubMed Web of Science ®Google Scholar
• Creech CB, Frenck RW, Fiquet A, et al. Persistence of immune responses through 36 months in healthy adults after vaccination with a novel staphylococcus aureus 4-antigen vaccine (SA4Ag). Open Forum Infect Dis. 2019;7(1). doi: 10.1093/ofid/ofz532
   PubMed Web of Science ®Google Scholar
• Smith W B, Abbanat D, Spiessens B, et al. 2712. Safety and immunogenicity of two doses of ExPEC4V vaccine against extraintestinal pathogenic Escherichia coli disease in healthy adult participants. Open Forum Infect Dis. 2019;6(Supplement_2):S954–S954. doi: 10.1093/ofid/ofz360.2389
   Google Scholar
• Frenck RW Jr., Ervin J, Chu L, et al. Safety and immunogenicity of a vaccine for extra-intestinal pathogenic Escherichia coli (ESTELLA): a phase 2 randomised controlled trial. Lancet Infect Dis. 2019 Jun;19(6):631–640. doi: 10.1016/S1473-3099(18)30803-X
   PubMed Web of Science ®Google Scholar
• Hülsdünker J, Thomas OS, Haring E, et al. Immunization against poly-N-acetylglucosamine reduces neutrophil activation and GVHD while sparing microbial diversity. Proc Natl Acad Sci, USA. 2019;116(41):20700–20706. doi: 10.1073/pnas.1908549116
   PubMed Web of Science ®Google Scholar
• Patel M, Kaufman DA. Anti-lipoteichoic acid monoclonal antibody (pagibaximab) studies for the prevention of staphylococcal bloodstream infections in preterm infants. Expert Opin Biol Ther. 2015 Apr;15(4):595–600. doi: 10.1517/14712598.2015.1019857
   PubMed Web of Science ®Google Scholar
• Chastre J, François B, Bourgeois M, et al. Safety, efficacy, and pharmacokinetics of gremubamab (MEDI3902), an anti-Pseudomonas aeruginosa bispecific human monoclonal antibody, in P. aeruginosa-colonised, mechanically ventilated intensive care unit patients: a randomised controlled trial. Crit Care. 2022 Nov 15;26(1):355. doi: 10.1186/s13054-022-04204-9
   PubMed Web of Science ®Google Scholar
• Loos A, Weich N, Woo J, et al. 674. Pre-Clinical and Phase I Safety Data for Anti-Pseudomonas aeruginosa Human Monoclonal Antibody AR-105. Open Forum Infect Dis. 2019;6(Supplement_2):S307–S308. doi: 10.1093/ofid/ofz360.742
   Google Scholar
• López-Sagaseta J, Malito E, Rappuoli R, et al. Self-assembling protein nanoparticles in the design of vaccines. Comput Struct Biotechnol J. 2016;14:58–68. doi: 10.1016/j.csbj.2015.11.001
   PubMed Web of Science ®Google Scholar
• Morelli L, Polito L, Richichi B, et al. Glyconanoparticles as tools to prevent antimicrobial resistance. Glycoconj J. 2021;38(4):475–490. doi: 10.1007/s10719-021-09988-6
   PubMed Web of Science ®Google Scholar
• Doan TA, Forward T, Tamburini BAJ. Trafficking and retention of protein antigens across systems and immune cell types.Cell Mol Life Sci. 2022;79(5):275. doi: 10.1007/s00018-022-04303-4
   PubMed Web of Science ®Google Scholar
• van der Put RMF, Metz B, Pieters RJ. Carriers and Antigens: new developments in glycoconjugate vaccines. Vaccines. 2023;11(2):219. doi: 10.3390/vaccines11020219
   Web of Science ®Google Scholar
• Zottig X, Côté-Cyr M, Arpin D, et al. Protein supramolecular structures: from self-assembly to nanovaccine design. Nanomaterials. 2020;10(5):1008. doi: 10.3390/nano10051008
   Web of Science ®Google Scholar
• Olshefsky A, Richardson C, Pun SH, et al. Engineering self-assembling protein nanoparticles for therapeutic delivery. Bioconjug Chem. 2022 Mar 16;33(11):2018–2034. doi: 10.1021/acs.bioconjchem.2c00030
   PubMedGoogle Scholar
• Fuenmayor J, Gòdia F, Cervera L. Production of virus-like particles for vaccines. N Biotechnol. 2017 Oct 25;39(Pt B):174–180. doi: 10.1016/j.nbt.2017.07.010
   PubMedGoogle Scholar
• Venters C, Graham W, Cassidy W. Recombivax-HB: perspectives past, present and future.Expert Rev Vaccines. 2004 June 1;3(2):119–129. doi: 10.1586/14760584.3.2.119
   PubMedGoogle Scholar
• Kheirollahpour M, Mehrabi M, Dounighi NM, et al. Nanoparticles and Vaccine Development. Pharm Nanotechnol. 2020;8(1):6–21. doi: 10.2174/2211738507666191024162042
   PubMedGoogle Scholar
• Polonskaya Z, Deng S, Sarkar A, et al. T cells control the generation of nanomolar-affinity anti-glycan antibodies. J Clin Invest. 2017 Apr 3;127(4):1491–1504. doi: 10.1172/JCI91192
   PubMed Web of Science ®Google Scholar
• Xu L, Li Z, Su Z, et al. Development of meningococcal polysaccharide conjugate vaccine that can elicit long-lasting and strong cellular immune response with hepatitis B core antigen virus-like particles as a novel carrier protein. Vaccine. 2019 Aug 8;37(7):956–964. doi: 10.1016/j.vaccine.2018.12.073
   PubMed Web of Science ®Google Scholar
• Rashidijahanabad Z, Kelly M, Kamruzzaman M, et al. Virus-like particle display of vibrio choleraeO-Specific polysaccharide as a potential vaccine against cholera. ACS Infect Dis. 2022 Mar 11;8(3):574–583. doi: 10.1021/acsinfecdis.1c00585
   PubMed Web of Science ®Google Scholar
• King NP, Sheffler W, Sawaya MR, et al. Computational design of self-assembling protein nanomaterials with atomic level accuracy. Science. 2012 Jun 1;336(6085):1171–1174. doi: 10.1126/science.1219364
   PubMed Web of Science ®Google Scholar
• Correnti CE, Hallinan JP, Doyle LA, et al. Engineering and functionalization of large circular tandem repeat protein nanoparticles. Nat Struct Mol Biol. 2020;27(4):342–350. doi: 10.1038/s41594-020-0397-5
   PubMed Web of Science ®Google Scholar
• Marcandalli J, Fiala B, Ols S, et al. Induction of potent neutralizing antibody responses by a designed protein nanoparticle vaccine for respiratory syncytial virus. Cell. 2019 Mar 7;176(6):1420–1431.e17. doi: 10.1016/j.cell.2019.01.046
   PubMed Web of Science ®Google Scholar
• Walls AC, Fiala B, Schäfer A, et al. Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2. Cell. 2020 Nov 25;183(5):1367–1382.e17. doi: 10.1016/j.cell.2020.10.043
   PubMed Web of Science ®Google Scholar
• Arunachalam PS, Walls AC, Golden N, et al. Adjuvanting a subunit COVID-19 vaccine to induce protective immunity. Nature. 2021 June 1;594(7862):253–258. doi: 10.1038/s41586-021-03530-2
   PubMed Web of Science ®Google Scholar
• Boyoglu-Barnum S, Ellis D, Gillespie RA, et al. Quadrivalent influenza nanoparticle vaccines induce broad protection. Nature. 2021 Apr;592(7855):623–628. doi: 10.1038/s41586-021-03365-x
   PubMed Web of Science ®Google Scholar
• Bernadac A, Gavioli M, Lazzaroni JC, et al. Escherichia coli tol-pal mutants form outer membrane vesicles. J Bacteriol. 1998 Sep;180(18):4872–4878. doi: 10.1128/JB.180.18.4872-4878.1998
   PubMed Web of Science ®Google Scholar
• Turner L, Praszkier J, Hutton ML, et al. Increased Outer Membrane Vesicle Formation in a Helicobacter pylori tolB Mutant. Helicobacter. 2015 Aug;20(4):269–283. doi: 10.1111/hel.12196
   PubMed Web of Science ®Google Scholar
• Mancini F, Micoli F, Necchi F, et al. GMMA-Based vaccines: the known and the unknown. Front Immunol. 2021;12:715393. doi: 10.3389/fimmu.2021.715393
   PubMed Web of Science ®Google Scholar
• Micoli F, Rossi O, Conti V, et al. Antibodies elicited by the shigella sonnei GMMA vaccine in adults trigger complement-mediated serum bactericidal activity: results from a phase 1 dose escalation trial followed by a booster extension. Front Immunol. 2021;12:671325. doi: 10.3389/fimmu.2021.671325
   PubMed Web of Science ®Google Scholar
• Di Benedetto R, Alfini R, Carducci M, et al. Novel simple conjugation chemistries for decoration of GMMA with Heterologous Antigens. Int J Mol Sci. 2021 Sep 22;22(19):10180. doi: 10.3390/ijms221910180
   PubMed Web of Science ®Google Scholar
• Palmieri E, Kis Z, Ozanne J, et al. GMMA as an alternative carrier for a glycoconjugate vaccine against group a streptococcus. Vaccines (Basel). 2022 Jun 28;10(7):1034. doi: 10.3390/vaccines10071034
   PubMed Web of Science ®Google Scholar
• Gasperini G, Alfini R, Arato V, et al. Salmonella Paratyphi A Outer Membrane Vesicles Displaying Vi Polysaccharide as a Multivalent Vaccine against Enteric Fever. Infect Immun. 2021 Mar 17;89(4). doi: 10.1128/IAI.00699-20
   PubMed Web of Science ®Google Scholar
• Micoli F, Alfini R, Di Benedetto R, et al. Generalized modules for membrane antigens as carrier for polysaccharides: impact of sugar length, density, and attachment site on the immune response elicited in animal models. Front Immunol. 2021;12:719315. doi: 10.3389/fimmu.2021.719315
   PubMed Web of Science ®Google Scholar
• Raso MM, Gasperini G, Alfini R, et al. GMMA and glycoconjugate approaches compared in mice for the development of a vaccine against shigella flexneri serotype 6. Vaccines (Basel). 2020 Apr 3;8(2):160. doi: 10.3390/vaccines8020160
   PubMed Web of Science ®Google Scholar
• Valguarnera E, Feldman MF. Glycoengineered outer membrane vesicles as a platform for vaccine development. Methods Enzymol. 2017;597:285–310.
   PubMed Web of Science ®Google Scholar
• Gnopo YMD, Watkins HC, Stevenson TC, et al. Designer outer membrane vesicles as immunomodulatory systems - reprogramming bacteria for vaccine delivery. Adv Drug Deliv Rev. 2017 May 15;114:132–142. doi: 10.1016/j.addr.2017.05.003
   PubMed Web of Science ®Google Scholar
• Chen L, Valentine JL, Huang CJ, et al. Outer membrane vesicles displaying engineered glycotopes elicit protective antibodies. Proc Natl Acad Sci, USA. 2016 Jun 28;113(26):E3609–18. doi: 10.1073/pnas.1518311113
   PubMed Web of Science ®Google Scholar
• Price NL, Goyette-Desjardins G, Nothaft H, et al. Glycoengineered Outer Membrane Vesicles: A Novel Platform for Bacterial Vaccines. Sci Rep. 2016 Apr 22;6(1):24931. doi: 10.1038/srep24931
   PubMedGoogle Scholar
• Stevenson TC, Cywes-Bentley C, Moeller TD, et al. Immunization with outer membrane vesicles displaying conserved surface polysaccharide antigen elicits broadly antimicrobial antibodies. Proc Natl Acad Sci, USA. 2018;115(14):E3106–E3115. doi: 10.1073/pnas.1718341115
   PubMed Web of Science ®Google Scholar
• Zhang F, Lu YJ, Malley R. Multiple antigen-presenting system (MAPS) to induce comprehensive B- and T-cell immunity. Proc Natl Acad Sci, USA. 2013 Aug 13;110(33):13564–13569. doi: 10.1073/pnas.1307228110
   PubMed Web of Science ®Google Scholar
• Zhang F, Thompson C, Ma N, et al. Carrier proteins facilitate the generation of antipolysaccharide immunity via multiple mechanisms. mBio. MBio. 2022 Jun 28;13(3):e0379021. doi: 10.1128/mbio.03790-21
   PubMed Web of Science ®Google Scholar
• Zhang F, Ledue O, Jun M, et al. Protection against staphylococcus aureus colonization and infection by B- and T-Cell-mediated mechanisms. MBio. 2018 Oct 16;9(5). doi: 10.1128/mBio.01949-18
   Web of Science ®Google Scholar
• Chichili GR, Smulders R, Santos V, et al. Phase 1/2 study of a novel 24-valent pneumococcal vaccine in healthy adults aged 18 to 64 years and in older adults aged 65 to 85 years. Vaccine. 2022 Jul 29;40(31):4190–4198. doi: 10.1016/j.vaccine.2022.05.079
   PubMed Web of Science ®Google Scholar
• Choi M, Tennant SM, Simon R, et al. Progress towards the development of klebsiella vaccines. Expert Rev Vaccines. 2019 Jul;18(7):681–691. doi: 10.1080/14760584.2019.1635460
   PubMed Web of Science ®Google Scholar
• CDC. Antibiotic resistance threats in the United States, 2019. Atlanta GA: US Department of Health and Human Services; 2019.
   Google Scholar
• Kaper JB, Nataro JP, Mobley HLT. Pathogenic Escherichia coli.Nature Rev Microbiol. 2004 Feb 1;2(2):123–140. doi: 10.1038/nrmicro818
   PubMed Web of Science ®Google Scholar
• Khalil IA, Troeger C, Blacker BF, et al. Morbidity and mortality due to shigella and enterotoxigenic Escherichia coli diarrhoea: the global burden of disease study 1990-2016. Lancet Infect Dis. 2018 Nov;18(11):1229–1240. doi: 10.1016/S1473-3099(18)30475-4
   PubMed Web of Science ®Google Scholar
• O’Brien VP, Hannan TJ, Nielsen HV, et al. Drug and vaccine development for the treatment and prevention of urinary tract infections. Microbiol Spectr. 2016 Feb;4(1). doi: 10.1128/microbiolspec.UTI-0013-2012
   PubMed Web of Science ®Google Scholar
• Brumbaugh AR, Mobley HL. Preventing urinary tract infection: progress toward an effective Escherichia coli vaccine. Expert Rev Vaccines. 2012 Jun;11(6):663–676. doi: 10.1586/erv.12.36
   PubMed Web of Science ®Google Scholar
• McLellan LK, Hunstad DA. Urinary tract infection: pathogenesis and outlook.Trends Mol Med. 2016 Nov 1;22(11):946–957. doi: 10.1016/j.molmed.2016.09.003
   PubMed Web of Science ®Google Scholar
• Pokharel P, Dhakal S, Dozois CM. The diversity of Escherichia coli Pathotypes and vaccination strategies against this versatile bacterial pathogen. Microorganisms. 2023;11(2):344. doi: 10.3390/microorganisms11020344
   PubMed Web of Science ®Google Scholar
• Chorro L, Li Z, Chu L, et al. Preclinical immunogenicity and efficacy of optimized O25b O-Antigen glycoconjugates to prevent MDR ST131 E. coli infections. Infect Immun. 2022 Apr 21;90(4):e0002222. doi: 10.1128/iai.00022-22
   PubMed Web of Science ®Google Scholar
• McGuinness WA, Malachowa N, DeLeo FR. Vancomycin resistance in staphylococcus aureus. Yale J Biol Med. 2017 Jun;90(2):269–281.
   PubMed Web of Science ®Google Scholar
• Olaniyi R, Pozzi C, Grimaldi L, et al. Staphylococcus aureus-associated skin and soft tissue infections: anatomical localization, epidemiology, therapy and potential prophylaxis. Curr Top Microbiol Immunol. 2017;409:199–227.
   PubMed Web of Science ®Google Scholar
• Humphreys H, Becker K, Dohmen PM, et al. Staphylococcus aureus and surgical site infections: benefits of screening and decolonization before surgery. J Hosp Infect. 2016;94(3):295–304. doi: 10.1016/j.jhin.2016.06.011
   PubMed Web of Science ®Google Scholar
• Gooch JR, Serazin A, Schwarm E, et al. Vaccines to tackle drug resistant infections - an evaluation of R&D opportunities the boston consulting group/wellcome trust. 2018. https://vaccinesforamr.org/
   Google Scholar
• Sands K, Carvalho MJ, Portal E, et al. Characterization of antimicrobial-resistant Gram-negative bacteria that cause neonatal sepsis in seven low- and middle-income countries. Nat Microbiol. 2021 Apr;6(4):512–523. doi: 10.1038/s41564-021-00870-7
   PubMed Web of Science ®Google Scholar
• Priebe GP, Goldberg JB. Vaccines for Pseudomonas aeruginosa: a long and winding road. Expert Rev Vaccines. 2014 Apr;13(4):507–519. doi: 10.1586/14760584.2014.890053
   PubMed Web of Science ®Google Scholar
• El Zowalaty ME, Al Thani AA, Webster TJ, et al. Pseudomonas aeruginosa: arsenal of resistance mechanisms, decades of changing resistance profiles, and future antimicrobial therapies. Future Microbiol. 2015;10(10):1683–1706. doi: 10.2217/fmb.15.48
   PubMed Web of Science ®Google Scholar
• Zhao M, Qin C, Li L, et al. Conjugation of synthetic trisaccharide of staphylococcus aureus type 8 capsular polysaccharide elicits antibodies recognizing intact bacterium. Front Chem. 2020;8:258. doi: 10.3389/fchem.2020.00258
   PubMed Web of Science ®Google Scholar
• Cheng BL, Nielsen TB, Pantapalangkoor P, et al. Evaluation of serotypes 5 and 8 capsular polysaccharides in protection against staphylococcus aureus in murine models of infection. Hum Vaccin Immunother. 2017 Jul 3;13(7):1609–1614. doi: 10.1080/21645515.2017.1304334
   PubMed Web of Science ®Google Scholar
• Yang FL, Lou TC, Kuo SC, et al. A medically relevant capsular polysaccharide in Acinetobacter baumannii is a potential vaccine candidate. Vaccine. 2017 Mar 7;35(10):1440–1447. doi: 10.1016/j.vaccine.2017.01.060
   PubMed Web of Science ®Google Scholar
• Rudenko N, Karatovskaya A, Zamyatina A, et al. Immune response to conjugates of fragments of the type K9 capsular polysaccharide of acinetobacter baumannii with carrier proteins. Microbiol Spectr. 2022 Oct 26;10(5):e0167422. doi: 10.1128/spectrum.01674-22
   PubMedGoogle Scholar
• Kobayashi SD, Porter AR, Freedman B, et al. Antibody-mediated killing of carbapenem-resistant ST258 Klebsiella pneumoniae by human neutrophils. MBio. 2018 Mar 13;9(2). doi: 10.1128/mBio.00297-18
   PubMed Web of Science ®Google Scholar
• Kalfopoulou E, Laverde D, Miklic K, et al. Development of Opsonic Mouse Monoclonal Antibodies against Multidrug-Resistant Enterococci. Infect Immun. 2019 Sep;87(9). doi: 10.1128/IAI.00276-19
   PubMed Web of Science ®Google Scholar
• Romero-Saavedra F, Laverde D, Kalfopoulou E, et al. Conjugation of different immunogenic enterococcal vaccine target antigens leads to extended strain coverage. J Infect Dis. 2019 Oct 8;220(10):1589–1598. doi: 10.1093/infdis/jiz357
   PubMed Web of Science ®Google Scholar
• Laverde D, Romero-Saavedra F, Argunov DA, et al. Synthetic oligomers mimicking capsular polysaccharide diheteroglycan are potential vaccine candidates against encapsulated enterococcal infections. ACS Infect Dis. 2020 Jul 10;6(7):1816–1826. doi: 10.1021/acsinfecdis.0c00063
   PubMed Web of Science ®Google Scholar
• Feldman MF, Mayer Bridwell AE, Scott NE, et al. A promising bioconjugate vaccine against hypervirulent Klebsiella pneumoniae. Proc Natl Acad Sci, USA. 2019 Sep 10;116(37):18655–18663. doi: 10.1073/pnas.1907833116
   PubMed Web of Science ®Google Scholar
• Ravinder M, Liao KS, Cheng YY, et al. A Synthetic Carbohydrate-Protein Conjugate Vaccine Candidate against Klebsiella pneumoniae Serotype K2. J Org Chem. 2020 Dec 18;85(24):15964–15997. doi: 10.1021/acs.joc.0c01404
   PubMed Web of Science ®Google Scholar
• Maleki M, Azimi S, Salouti M. Protective effect of two new nanovaccines against Pseudomonas aeruginosa based on LPS and OPS: a comparison study. Immunobiol. 2022 Nov;227(6):152278. doi: 10.1016/j.imbio.2022.152278
   PubMed Web of Science ®Google Scholar
• Najafzadeh F, Tanomand A, Hadadi A, et al. Immunological Properties of Exotoxin A Toxoid - Detoxified Lipopolysaccharide - Gold Nanoparticles Conjugate Against Pseudomonas aeruginosa Infection. Iran J Immunol. 2021;18(4):292–303. doi: 10.22034/IJI.2021.87816.1832
   PubMed Web of Science ®Google Scholar
• Hegerle N, Choi M, Sinclair J, et al. Development of a broad spectrum glycoconjugate vaccine to prevent wound and disseminated infections with Klebsiella pneumoniae and Pseudomonas aeruginosa. PLoS One. 2018;13(9):e0203143. doi: 10.1371/journal.pone.0203143
   PubMed Web of Science ®Google Scholar
• Cross AT, Michon F. Novel multivalent vaccine for Gram-negative bacterial pathogens including multiple antibiotic resistant strains. 18th Annual World Vaccine Congress; (WA) DC USA 2019.
   Google Scholar
• Naini A, Bartetzko MP, Sanapala SR, et al. Semisynthetic glycoconjugate vaccine candidates against Escherichia coli O25B induce functional IgG antibodies in mice. J Am Chem Soc Au. 2022;2(9):2135–2151. doi: 10.1021/jacsau.2c00401
   Google Scholar
• Williams AJ, Warfel KF, Desai P, et al. A low-cost recombinant glycoconjugate vaccine confers immunogenicity and protection against enterotoxigenic Escherichia coli infections in mice [original research]. Front Mol Biosci. 2023 Mar 2;10:10.
   Web of Science ®Google Scholar
• Kong L, Vijayakrishnan B, Kowarik M, et al. An antibacterial vaccination strategy based on a glycoconjugate containing the core lipopolysaccharide tetrasaccharide Hep2Kdo2. Nat Chem. 2016 Mar 1;8(3):242–249. doi: 10.1038/nchem.2432
   PubMed Web of Science ®Google Scholar
• Jamshidi MP, Cairns C, Chong S, et al. Synthesis and immunogenicity of a methyl rhamnan pentasaccharide conjugate from Pseudomonas aeruginosa A-Band polysaccharide. ACS Infect Dis. 2022 Jul 8;8(7):1347–1355. doi: 10.1021/acsinfecdis.2c00184
   PubMed Web of Science ®Google Scholar
• Zhang L, Zhang Y, Hua Q, et al. Promoter-controlled synthesis and antigenic evaluation of mannuronic acid alginate glycans of Pseudomonas aeruginosa. Org Lett. 2022 Nov 18;24(45):8381–8386. doi: 10.1021/acs.orglett.2c03439
   PubMed Web of Science ®Google Scholar
• Azimi S, Safari Zanjani L. Immunization against Pseudomonas aeruginosa using Alg-PLGA nano-vaccine. Iran J Basic Med Sci. 2021 Apr;24(4):476–482. doi: 10.22038/ijbms.2021.52217.11813
   PubMed Web of Science ®Google Scholar
• Afshari H, Maleki M, Hakimian M, et al. Immunogenicity evaluating of the SLNs-alginate conjugate against Pseudomonas aeruginosa. J Immunol Methods. 2021 Jan;488:112938.
   PubMed Web of Science ®Google Scholar
• Farjah A, Owlia P, Siadat SD, et al. Immunological evaluation of an alginate-based conjugate as a vaccine candidate against Pseudomonas aeruginosa. APMIS. 2015 Feb;123(2):175–183. doi: 10.1111/apm.12337
   PubMed Web of Science ®Google Scholar
• Gonzaga ZJC, Merakou C, DiGiandomenico A, et al. A Pseudomonas aeruginosa-Derived Particulate Vaccine Protects against P. aeruginosa Infection. Vaccines (Basel). 2021 Jul 20;9(7):803. doi: 10.3390/vaccines9070803
   PubMed Web of Science ®Google Scholar
• Lee JW, Parlane NA, Wedlock DN, et al. Bioengineering a bacterial pathogen to assemble its own particulate vaccine capable of inducing cellular immunity. Sci Rep. 2017;7(1):41607. doi: 10.1038/srep41607
   PubMedGoogle Scholar
• Lee IM, Yang F-L, Chen T-L, et al. Pseudaminic acid on exopolysaccharide of acinetobacter baumannii plays a critical role in phage-assisted preparation of glycoconjugate vaccine with high antigenicity. J Am Chem Soc. 2018 July 18;140(28):8639–8643. doi: 10.1021/jacs.8b04078
   PubMed Web of Science ®Google Scholar
• Wei R, Yang X, Liu H, et al. Synthetic pseudaminic-acid-based antibacterial vaccine confers effective protection against acinetobacter baumannii infection. ACS Cent Sci. 2021 Sep 22;7(9):1535–1542. doi: 10.1021/acscentsci.1c00656
   PubMed Web of Science ®Google Scholar
• Kodali S, Vinogradov E, Lin F, et al. A vaccine approach for the prevention of infections by multidrug-resistant Enterococcus faecium. J Biol Chem. 2015 Aug 7;290(32):19512–19526. doi: 10.1074/jbc.M115.655852
   PubMed Web of Science ®Google Scholar
• Gholami SA, Goli HR, Haghshenas MR, et al. Evaluation of polysaccharide intercellular adhesion (PIA) and glycerol teichoic acid (gly-TA) arisen antibodies to prevention of biofilm formation in staphylococcus aureus and Staphylococcus epidermidis strains. BMC Res Notes. 2019 Oct 25;12(1):691. doi: 10.1186/s13104-019-4736-8
   PubMed Web of Science ®Google Scholar
• Laverde D, Wobser D, Romero-Saavedra F, et al. Synthetic teichoic acid conjugate vaccine against nosocomial gram-positive bacteria. PLoS One. 2014;9(10):e110953. doi: 10.1371/journal.pone.0110953
   PubMed Web of Science ®Google Scholar
• Zhou Z, Ding W, Li C, et al. Synthesis and immunological study of a wall teichoic acid-based vaccine against E. faecium U0317. J Carbohydr Chem. 2017 June 13;36(4–6):205–219. doi: 10.1080/07328303.2017.1390576
   Web of Science ®Google Scholar
• Micoli F, Romano MR, Carboni F, et al. Strengths and weaknesses of pneumococcal conjugate vaccines. Glycoconj J. 2023 Apr;40(2):135–148. doi: 10.1007/s10719-023-10100-3
   PubMed Web of Science ®Google Scholar
• Converso TR, Assoni L, André GO, et al. The long search for a serotype independent pneumococcal vaccine. Expert Rev Vaccines. 2020 Jan 2;19(1):57–70. doi: 10.1080/14760584.2020.1711055
   PubMed Web of Science ®Google Scholar
• Ali S, Berni F, Enotarpi J, et al. Synthetic teichoic acid chemistry for vaccine applications. In: Rauter A, Christensen B, Somsák L, et al. Recent trends in carbohydrate chemistry 2 . Elsevier; 2020. p. 207–238 doi: 10.1016/B978-0-12-820954-7.00006-2
   Google Scholar
• Le Mauff F, Razvi E, Reichhardt C, et al. The pel polysaccharide is predominantly composed of a dimeric repeat of α-1,4 linked galactosamine and N-acetylgalactosamine. Commun Biol. 2022 May 26;5(1):502. doi: 10.1038/s42003-022-03453-2
   PubMed Web of Science ®Google Scholar
• Franklin M, Nivens D, Weadge J, et al. Biosynthesis of the Pseudomonas aeruginosa Extracellular Polysaccharides, Alginate, Pel, and Psl [Review]. Front Microbiol. 2011 Aug 22;2. doi: 10.3389/fmicb.2011.00167
   Web of Science ®Google Scholar
• van Dalen R, Peschel A, van Sorge NM. Wall teichoic acid in staphylococcus aureus host interaction. Trends Microbiol. 2020;28(12):985–998. doi: 10.1016/j.tim.2020.05.017
   PubMed Web of Science ®Google Scholar
• Hsieh SA, Allen PM. Immunomodulatory roles of polysaccharide capsules in the intestine. Front Immunol. 2020;11:690. doi: 10.3389/fimmu.2020.00690
   PubMed Web of Science ®Google Scholar
• Caroff M, Novikov A. Lipopolysaccharides: structure, function and bacterial identifications☆☆☆. OCL. 2020;27:31. doi: 10.1051/ocl/2020025
   Google Scholar
• Zhu H, Rollier CS, Pollard AJ. Recent advances in lipopolysaccharide-based glycoconjugate vaccines.Expert Rev Vaccines. 2021 Dec 2;20(12):1515–1538. doi: 10.1080/14760584.2021.1984889
   PubMed Web of Science ®Google Scholar
• Singh R, Capalash N, Sharma P. Vaccine development to control the rising scourge of antibiotic-resistant acinetobacter baumannii: a systematic review. 3 Biotech. 2022 Mar;12(3):85. doi: 10.1007/s13205-022-03148-9
   PubMedGoogle Scholar
• Giguère D. Surface polysaccharides from acinetobacter baumannii: structures and syntheses. Carbohydr Res. 2015;418:29–43. doi: 10.1016/j.carres.2015.10.001
   PubMed Web of Science ®Google Scholar
• Russo TA, Beanan JM, Olson R, et al. The K1 capsular polysaccharide from Acinetobacter baumannii is a potential therapeutic target via passive immunization. Infect Immun. 2013 Mar;81(3):915–922. doi: 10.1128/IAI.01184-12
   PubMed Web of Science ®Google Scholar
• Sianturi J, Priegue P, Hu J, et al. Semi-synthetic glycoconjugate vaccine lead against acinetobacter baumannii 17978. Angew Chem Int Ed Engl. 2022 Oct 10;61(41):e202209556. doi: 10.1002/anie.202209556
   PubMed Web of Science ®Google Scholar
• Li X, Pan C, Liu Z, et al. Safety and immunogenicity of a new glycoengineered vaccine against acinetobacter baumannii in mice. Microbiol Biotechnol. 2022 Feb;15(2):703–716. doi: 10.1111/1751-7915.13770
   Google Scholar
• Pantophlet R, Nemec A, Brade L, et al. O-antigen diversity among acinetobacter baumannii strains from the Czech Republic and Northwestern Europe, as determined by lipopolysaccharide-specific monoclonal antibodies. J Clin Microbiol. 2001 Jul;39(7):2576–2580. doi: 10.1128/JCM.39.7.2576-2580.2001
   PubMed Web of Science ®Google Scholar
• Whitfield C. Biosynthesis and assembly of capsular polysaccharides in Escherichia coli. Annu Rev Biochem. 2006;75(1):39–68. doi: 10.1146/annurev.biochem.75.103004.142545
   PubMedGoogle Scholar
• Huttner A, Hatz C, Dobbelsteen G, et al. Safety, immunogenicity, and preliminary clinical efficacy of a vaccine against extraintestinal pathogenic Escherichia coli in women with a history of recurrent urinary tract infection: a randomised, single-blind, placebo-controlled phase 1b trial. Lancet Infect Dis. 2017 Feb 01;17(5):528–537. doi: 10.1016/S1473-3099(17)30108-1
   PubMed Web of Science ®Google Scholar
• Nesta B, Valeri M, Spagnuolo A, et al. SslE elicits functional antibodies that impair in vitro mucinase activity and in vivo colonization by both intestinal and extraintestinal Escherichia coli strains. PLOS Pathog. 2014 May;10(5):e1004124. doi: 10.1371/journal.ppat.1004124
   PubMed Web of Science ®Google Scholar
• Riaz S, Steinsland H, Thorsing M, et al. Characterization of glycosylation-specific systemic and mucosal IgA antibody responses to Escherichia coli mucinase YghJ (SslE). Front Immunol. 2021;12:760135. doi: 10.3389/fimmu.2021.760135
   PubMed Web of Science ®Google Scholar
• Szardenings M, Kern K, Delaroque N, et al. Glycosylation of bacterial antigens changes epitope patterns. Front Immunol. 2023;14:1258136. doi: 10.3389/fimmu.2023.1258136
   PubMedGoogle Scholar
• Huebner J, Wang Y, Krueger WA, et al. Isolation and chemical characterization of a capsular polysaccharide antigen shared by clinical isolates of Enterococcus faecalis and vancomycin-resistant Enterococcus faecium. Infect Immun. 1999 Mar;67(3):1213–1219. doi: 10.1128/IAI.67.3.1213-1219.1999
   PubMed Web of Science ®Google Scholar
• Wang Y, Huebner J, Tzianabos AO, et al. Structure of an antigenic teichoic acid shared by clinical isolates of Enterococcus faecalis and vancomycin-resistant Enterococcus faecium. Carbohydr Res. 1999 Mar 31;316(1–4):155–160. doi: 10.1016/S0008-6215(99)00046-4
   PubMed Web of Science ®Google Scholar
• Hufnagel M, Carey VJ, Baldassarri L, et al. Distribution of four capsular serotypes of Enterococcus faecalis among clinical isolates from different geographical origins and infection sites. Infection. 2006 Feb;34(1):22–25. doi: 10.1007/s15010-006-4100-5
   PubMed Web of Science ®Google Scholar
• Huebner J, Quaas A, Krueger WA, et al. Prophylactic and therapeutic efficacy of antibodies to a capsular polysaccharide shared among vancomycin-sensitive and -resistant enterococci. Infect Immun. 2000 Aug;68(8):4631–4636. doi: 10.1128/IAI.68.8.4631-4636.2000
   PubMed Web of Science ®Google Scholar
• Theilacker C, Kaczyński Z, Kropec A, et al. Serodiversity of opsonic antibodies against Enterococcus faecalis–glycans of the cell wall revisited. PLoS One. 2011 Mar 18;6(3):e17839. doi: 10.1371/journal.pone.0017839
   PubMed Web of Science ®Google Scholar
• Ali L, Blum HE, Sakιnç T. Detection and characterization of bacterial polysaccharides in drug-resistant enterococci.Glycoconj J. 2019;36(5):429–438. doi: 10.1007/s10719-019-09881-3
   PubMed Web of Science ®Google Scholar
• Palmer KL, Godfrey P, Griggs A, et al. Comparative genomics of enterococci: variation in Enterococcus faecalis, clade structure in E. faecium, and defining characteristics of E. gallinarum and E. casseliflavus. MBio. 2012;3(1):e00318–11. doi: 10.1128/mBio.00318-11
   PubMed Web of Science ®Google Scholar
• Ali L, Spiess M, Wobser D, et al. Identification and functional characterization of the putative polysaccharide biosynthesis protein (CapD) of enterococcus faecium U0317. Infect Genet Evol. 2016;37:215–224.
   PubMed Web of Science ®Google Scholar
• Bychowska A, Theilacker C, Czerwicka M, et al. Chemical structure of wall teichoic acid isolated from enterococcus faecium strain U0317. Carbohydr Res. 2011 Dec 13;346(17):2816–2819. doi: 10.1016/j.carres.2011.09.026
   PubMed Web of Science ®Google Scholar
• Pan Y-J, Lin T-L, Chen C-T, et al. Genetic analysis of capsular polysaccharide synthesis gene clusters in 79 capsular types of klebsiella spp. Sci Rep. 2015 Oct 23;5(1):15573. doi: 10.1038/srep15573
   PubMedGoogle Scholar
• Edelman R, Taylor DN, Wasserman SS, et al. Phase 1 trial of a 24-valent Klebsiella capsular polysaccharide vaccine and an eight-valent Pseudomonas O-polysaccharide conjugate vaccine administered simultaneously. Vaccine. 1994 Nov;12(14):1288–1294. doi: 10.1016/S0264-410X(94)80054-4
   PubMed Web of Science ®Google Scholar
• Granström M, Wretlind B, Markman B, et al. Enzyme-linked immunosorbent assay to evaluate the immunogenicity of a polyvalent Klebsiella capsular polysaccharide vaccine in humans. J Clin Microbiol. 1988 Nov;26(11):2257–2261. doi: 10.1128/jcm.26.11.2257-2261.1988
   PubMed Web of Science ®Google Scholar
• Cryz SJ Jr., Mortimer P, Cross AS, et al. Safety and immunogenicity of a polyvalent Klebsiella capsular polysaccharide vaccine in humans. Vaccine. 1986 Mar;4(1):15–20. doi: 10.1016/0264-410X(86)90092-7
   PubMed Web of Science ®Google Scholar
• Arato V, Raso MM, Gasperini G, et al. Prophylaxis and treatment against Klebsiella pneumoniae: Current insights on this emerging anti-microbial resistant global threat. Int J Mol Sci. 2021 Apr 14;22(8):4042. doi: 10.3390/ijms22084042
   PubMed Web of Science ®Google Scholar
• Alexander JW, Fisher MW, MacMillan BG. Immunological control of pseudomonas infection in burn patients: a clinical evaluation. Arch Surg. 1971 Jan;102(1):31–35. doi: 10.1001/archsurg.1971.01350010033008
   PubMedGoogle Scholar
• Haghbin M, Armstrong D, Murphy ML. Controlled prospective trial of Pseudomonas aeruginosa vaccine in children with acute leukemia. Cancer. 1973;32(4):761–766. doi: 10.1002/1097-0142(197310)32:4<761:AID-CNCR2820320405>3.0.CO;2-H
   PubMed Web of Science ®Google Scholar
• Young LS, Meyer RD, Armstrong D. Pseudomonas aeruginosa vaccine in cancer patients. Ann Intern Med. 1973 Oct;79(4):518–527. doi: 10.7326/0003-4819-79-4-518
   PubMed Web of Science ®Google Scholar
• Pennington JE, Reynolds HY, Wood RE, et al. Use of a Pseudomonas Aeruginosa vaccine in patients with acute leukemia and cystic fibrosis. Am J Med. 1975 May;58(5):629–636. doi: 10.1016/0002-9343(75)90498-2
   PubMed Web of Science ®Google Scholar
• Hortobagyi GN, Gutterman JU, Snyder RD, et al. Pseudomonas vaccine: a phase I evaluation for cancer research. Cancer Immunol Immunother. 1978;4(3):201–207. doi: 10.1007/BF00204741
   Web of Science ®Google Scholar
• MacIntyre S, McVeigh T, Owen P. Immunochemical and biochemical analysis of the polyvalent Pseudomonas aeruginosa vaccine PEV. Infect Immun. 1986 Feb;51(2):675–686. doi: 10.1128/iai.51.2.675-686.1986
   PubMed Web of Science ®Google Scholar
• Jones RJ, Roe EA, Gupta JL. Low mortality in burned patients in a pseudomonas vaccine trial. Lancet. 1978 Aug 19;2(8086):401–403. doi: 10.1016/S0140-6736(78)91868-8
   PubMed Web of Science ®Google Scholar
• Langford DT, Hiller J. Prospective, controlled study of a polyvalent pseudomonas vaccine in cystic fibrosis–three year results. Arch Dis Child. 1984 Dec;59(12):1131–1134. doi: 10.1136/adc.59.12.1131
   PubMed Web of Science ®Google Scholar
• Döring G, Pier GB. Vaccines and immunotherapy against Pseudomonas aeruginosa. Vaccine. 2008 Feb 20;26(8):1011–1024. doi: 10.1016/j.vaccine.2007.12.007
   PubMed Web of Science ®Google Scholar
• Cryz SJ Jr., Fürer E, Cross AS, et al. Safety and immunogenicity of a Pseudomonas aeruginosa O-polysaccharide toxin A conjugate vaccine in humans. J Clin Investig. 1987 July 01;80(1):51–56. doi: 10.1172/JCI113062
   PubMed Web of Science ®Google Scholar
• Cryz SJ, Sadoff JC, Fürer E. Octavalent Pseudomonas aeruginosa O-polysaccharide-toxin A conjugate vaccine.Microb Pathog. 1989 Jan 1;6(1):75–80. doi: 10.1016/0882-4010(89)90010-7
   PubMed Web of Science ®Google Scholar
• Lang AB, Rüdeberg A, Schöni MH, et al. Vaccination of cystic fibrosis patients against Pseudomonas aeruginosa reduces the proportion of patients infected and delays time to infection. Pediatr Infect Dis J. 2004 Jun;23(6):504–510. doi: 10.1097/01.inf.0000129688.50588.ac
   PubMed Web of Science ®Google Scholar
• Cryz SJ Jr., Wedgwood J, Lang AB, et al. Immunization of noncolonized cystic fibrosis patients against Pseudomonas aeruginosa. J Infect Dis. 1994;169(5):1159–1162. doi: 10.1093/infdis/169.5.1159
   PubMed Web of Science ®Google Scholar
• Killough M, Rodgers AM, Ingram RJ. Pseudomonas aeruginosa: Recent Advances in Vaccine Development. Vaccines (Basel). 2022 Jul 8;10(7). doi: 10.3390/vaccines10071100
   PubMed Web of Science ®Google Scholar
• Cairns CM, Michael FS, Jamshidi M, et al. Structural characterization and evaluation of an epitope at the tip of the A-Band rhamnan polysaccharide of Pseudomonas aeruginosa. ACS Infect Dis. 2022;8(7):1336–1346. doi: 10.1021/acsinfecdis.2c00183
   PubMed Web of Science ®Google Scholar
• Nanra JS, Buitrago SM, Crawford S, et al. Capsular polysaccharides are an important immune evasion mechanism for Staphylococcus aureus. Hum Vaccin Immunother. 2013 Mar;9(3):480–487. doi: 10.4161/hv.23223
   PubMed Web of Science ®Google Scholar
• Lockhart SP, Scott DA, Jansen KU, et al. Glycoconjugate vaccines: the clinical journey. Carbohydrate-based vaccines: from concept to clinic. ACS symposium series. Vol. 1290. USA: American Chemical Society; 2018. p. 7–59 doi: 10.1021/bk-2018-1290.ch002
   Google Scholar
• Fattom AI, Horwith G, Fuller S, et al. Development of StaphVAX, a polysaccharide conjugate vaccine against S. aureus infection: from the lab bench to phase III clinical trials. Vaccine. 2004 Feb 17;22(7):880–887. doi: 10.1016/j.vaccine.2003.11.034
   PubMed Web of Science ®Google Scholar
• Fattom A, Fuller S, Propst M, et al. Safety and immunogenicity of a booster dose of staphylococcus aureus types 5 and 8 capsular polysaccharide conjugate vaccine (StaphVAX) in hemodialysis patients. Vaccine. 2004 Dec 16;23(5):656–663. doi: 10.1016/j.vaccine.2004.06.043
   PubMed Web of Science ®Google Scholar
• Fattom A, Matalon A, Buerkert J, et al. Efficacy profile of a bivalent staphylococcus aureus glycoconjugated vaccine in adults on hemodialysis: phase III randomized study. Hum Vaccin Immunother. 2015;11(3):632–641. doi: 10.4161/hv.34414
   PubMed Web of Science ®Google Scholar
• Levy J, Licini L, Haelterman E, et al. Safety and immunogenicity of an investigational 4-component staphylococcus aureus vaccine with or without AS03B adjuvant: results of a randomized phase I trial. Hum Vaccin Immunother. 2015;11(3):620–631. doi: 10.1080/21645515.2015.1011021
   PubMed Web of Science ®Google Scholar
• Nissen M, Marshall H, Richmond P, et al. A randomized phase I study of the safety and immunogenicity of three ascending dose levels of a 3-antigen staphylococcus aureus vaccine (SA3Ag) in healthy adults. Vaccine. 2015 Apr 8;33(15):1846–1854. doi: 10.1016/j.vaccine.2015.02.024
   PubMed Web of Science ®Google Scholar
• Frenck RW Jr., Creech CB, Sheldon EA, et al. Safety, tolerability, and immunogenicity of a 4-antigen staphylococcus aureus vaccine (SA4Ag): results from a first-in-human randomised, placebo-controlled phase 1/2 study. Vaccine. 2017 Jan 5;35(2):375–384. doi: 10.1016/j.vaccine.2016.11.010
   PubMed Web of Science ®Google Scholar
• Fattom A, Li X, Cho YH, et al. Effect of conjugation methodology, carrier protein, and adjuvants on the immune response to staphylococcus aureus capsular polysaccharides. Vaccine. 1995 Oct;13(14):1288–1293. doi: 10.1016/0264-410X(95)00052-3
   PubMed Web of Science ®Google Scholar
• Bagnoli F, Bertholet S, Grandi G. Inferring reasons for the failure of staphylococcus aureus vaccines in clinical trials [opinion]. Front Cell Infect Microbiol. 2012 Feb 22;2. doi: 10.3389/fcimb.2012.00016
   PubMed Web of Science ®Google Scholar
• Pier GB. Will there ever be a universal Staphylococcus aureus vaccine?Hum Vaccines Immunother. 2013;9(9):1865–1876. doi: 10.4161/hv.25182
   PubMed Web of Science ®Google Scholar
• Elli S, Alekseeva A, Ramakrishnan B, et al. Characterization of an antibody recognizing the conserved inner core of Pseudomonas aeruginosa lipopolysaccharides. Biochemistry. 2020;59(43):4202–4211. doi: 10.1021/acs.biochem.0c00642
   PubMed Web of Science ®Google Scholar
• van Dalen R, Molendijk MM, Ali S, et al. Do not discard Staphylococcus aureus WTA as a vaccine antigen. Nature. 2019;572(7767):E1–E2. doi: 10.1038/s41586-019-1416-8
   PubMed Web of Science ®Google Scholar
• Di Carluccio C, Soriano-Maldonado P, Berni F, et al. Antibody recognition of different staphylococcus aureus wall teichoic acid glycoforms. ACS Cent Sci. 2022;8(10):1383–1392. doi: 10.1021/acscentsci.2c00125
   PubMedGoogle Scholar
• Berni F, Kalfopoulou E, Gimeno Cardells AM, et al. Epitope recognition of a Monoclonal antibody raised against a synthetic glycerol phosphate based teichoic acid. ACS Chem Biol. 2021;16(8):1344–1349. doi: 10.1021/acschembio.1c00422
   PubMed Web of Science ®Google Scholar
• van der Es D, Hogendorf WFJ, Overkleeft HS, et al. Teichoic acids: synthesis and applications [10.1039/C6CS00270F]. Chem Soc Rev. 2017;46(5):1464–1482. doi: 10.1039/C6CS00270F
   PubMed Web of Science ®Google Scholar
• Theilacker C, Kropec A, Hammer F, et al. Protection against staphylococcus aureus by antibody to the polyglycerolphosphate backbone of heterologous lipoteichoic acid. J Infect Dis. 2012;205(7):1076–1085. doi: 10.1093/infdis/jis022
   PubMed Web of Science ®Google Scholar
• Yi X-Y, Huang Z-X, Hou X-R, et al. Immunization with a peptide mimicking lipoteichoic acid protects mice against staphylococcus aureus infection. Vaccine. 2019;37(31):4325–4335. doi: 10.1016/j.vaccine.2019.06.024
   PubMed Web of Science ®Google Scholar
• Balducci E, Papi F, Capialbi DE, et al. Polysaccharides’ structures and functions in biofilm architecture of antimicrobial-resistant (AMR) pathogens. Int J Mol Sci. 2023 Feb 17;24(4):4030. doi: 10.3390/ijms24044030
   PubMed Web of Science ®Google Scholar
• Jennings LK, Storek KM, Ledvina HE, et al. Pel is a cationic exopolysaccharide that cross-links extracellular DNA in the Pseudomonas aeruginosa biofilm matrix. Proc Natl Acad Sci, USA. 2015 Sep 8;112(36):11353–11358. doi: 10.1073/pnas.1503058112
   PubMed Web of Science ®Google Scholar
• Colvin KM, Irie Y, Tart CS, et al. The pel and Psl polysaccharides provide Pseudomonas aeruginosa structural redundancy within the biofilm matrix. Environ Microbiol. 2012 Aug;14(8):1913–1928. doi: 10.1111/j.1462-2920.2011.02657.x
   PubMed Web of Science ®Google Scholar
• Mishra M, Byrd MS, Sergeant S, et al. Pseudomonas aeruginosa psl polysaccharide reduces neutrophil phagocytosis and the oxidative response by limiting complement-mediated opsonization. Cell Microbiol. 2012 Jan;14(1):95–106. doi: 10.1111/j.1462-5822.2011.01704.x
   PubMed Web of Science ®Google Scholar
• DiGiandomenico A, Warrener P, Hamilton M, et al. Identification of broadly protective human antibodies to Pseudomonas aeruginosa exopolysaccharide psl by phenotypic screening. J Exp Med. 2012 Jul 2;209(7):1273–1287. doi: 10.1084/jem.20120033
   PubMed Web of Science ®Google Scholar
• Ali SO, Yu XQ, Robbie GJ, et al. Phase 1 study of MEDI3902, an investigational anti-Pseudomonas aeruginosa PcrV and psl bispecific human monoclonal antibody, in healthy adults. Clin Microbiol Infect. 2019 May;25(5):.e629.1–.e629.6. doi: 10.1016/j.cmi.2018.08.004
   Web of Science ®Google Scholar
• Ray VA, Hill PJ, Stover CK, et al. Anti-psl targeting of Pseudomonas aeruginosa biofilms for neutrophil-mediated disruption. Sci Rep. 2017 Nov 22;7(1):16065. doi: 10.1038/s41598-017-16215-6
   PubMedGoogle Scholar
• Skurnik D, Cywes-Bentley C, Pier GB. The exceptionally broad-based potential of active and passive vaccination targeting the conserved microbial surface polysaccharide PNAG. Expert Rev Vaccines. 2016 Aug;15(8):1041–1053. doi: 10.1586/14760584.2016.1159135
   PubMed Web of Science ®Google Scholar
• Maira-Litrán T, Kropec A, Abeygunawardana C, et al. Immunochemical properties of the staphylococcal poly-N-acetylglucosamine surface polysaccharide. Infect Immun. 2002 Aug;70(8):4433–4440. doi: 10.1128/IAI.70.8.4433-4440.2002
   PubMed Web of Science ®Google Scholar
• Maira-Litrán T, Kropec A, Goldmann DA, et al. Comparative opsonic and protective activities of staphylococcus aureus conjugate vaccines containing native or deacetylated staphylococcal poly-N-acetyl-beta-(1-6)-glucosamine. Infect Immun. 2005 Oct;73(10):6752–6762. doi: 10.1128/IAI.73.10.6752-6762.2005
   PubMed Web of Science ®Google Scholar
• Maira-Litran T, Kropec A, Goldmann D, et al. Biologic properties and vaccine potential of the staphylococcal poly-N-acetyl glucosamine surface polysaccharide. Vaccine. 2004;22(7):872–879. doi: 10.1016/j.vaccine.2003.11.033
   PubMed Web of Science ®Google Scholar
• Pozzi C, Waters EM, Rudkin JK, et al. Methicillin resistance alters the biofilm phenotype and attenuates virulence in staphylococcus aureus device-associated infections. PLOS Pathog. 2012;8(4):e1002626. doi: 10.1371/journal.ppat.1002626
   PubMed Web of Science ®Google Scholar
• Gening ML, Pier GB, Nifantiev NE. Broadly protective semi-synthetic glycoconjugate vaccine against pathogens capable of producing poly-β-(1→6)-N-acetyl-d-glucosamine exopolysaccharide. Drug Discov Today Technol. 2020;35-36:13–21. doi: 10.1016/j.ddtec.2020.09.002
   PubMedGoogle Scholar
• Soliman C, Walduck AK, Yuriev E, et al. Structural basis for antibody targeting of the broadly expressed microbial polysaccharide poly-N-acetylglucosamine. J Biol Chem. 2018;293(14):5079–5089. doi: 10.1074/jbc.RA117.001170
   PubMed Web of Science ®Google Scholar
• Bentancor LV, O’Malley JM, Bozkurt-Guzel C, et al. Poly-N-acetyl-β-(1-6)-glucosamine is a target for protective immunity against acinetobacter baumannii infections. Infect Immun. 2012 Feb;80(2):651–656. doi: 10.1128/IAI.05653-11
   PubMed Web of Science ®Google Scholar
• McDonald ND, Boyd EF. Structural and biosynthetic diversity of Nonulosonic acids (NulOs) that decorate surface structures in bacteria. Trends Microbiol. 2021;29(2):142–157. doi: 10.1016/j.tim.2020.08.002
   PubMed Web of Science ®Google Scholar
• Berti F, Adamo R. Recent mechanistic insights on glycoconjugate vaccines and future perspectives.ACS Chem Biol. 2013;8(8):1653–1663. doi: 10.1021/cb400423g
   PubMed Web of Science ®Google Scholar
• Kenyon JJ, Kasimova AA, Notaro A, et al. Acinetobacter baumannii K13 and K73 capsular polysaccharides differ only in K-unit side branches of novel non-2-ulosonic acids: di-N-acetylated forms of either acinetaminic acid or 8-epiacinetaminic acid. Carbohydr Res. 2017 Nov 27;452:149–155. doi: 10.1016/j.carres.2017.10.005
   PubMed Web of Science ®Google Scholar
• Weiner LM, Webb AK, Limbago B, et al. Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the national healthcare Safety network at the Centers for Disease Control and Prevention, 2011–2014. Infect Control Hosp Epidemiol. 2016;37(11):1288–1301. doi: 10.1017/ice.2016.174
   PubMed Web of Science ®Google Scholar
• Weiner-Lastinger LM, Abner S, Edwards JR, et al. Antimicrobial-resistant pathogens associated with adult healthcare-associated infections: summary of data reported to the national healthcare Safety network, 2015-2017. Infect Control Hosp Epidemiol. 2020 Jan;41(1):1–18. doi: 10.1017/ice.2019.296
   PubMed Web of Science ®Google Scholar
• Bonten M, Johnson JR, van den Biggelaar AHJ, et al. Epidemiology of Escherichia coli Bacteremia: A Systematic Literature Review. Clin Infect Dis. 2021 Apr 8;72(7):1211–1219. doi: 10.1093/cid/ciaa210
   PubMed Web of Science ®Google Scholar
• Liu Y, Zhu M, Fu X, et al. Escherichia coli causing neonatal meningitis during 2001-2020: a study in Eastern China. Int J Gen Med. 2021;14:3007–3016. doi: 10.2147/IJGM.S317299
   PubMed Web of Science ®Google Scholar
• Zhang W, Wang Q, Zhang L, et al. Comparison of epidemiological characteristics between ESBL and non-ESBL isolates of clinically isolated Escherichia coli from 2014 to 2022: a single-center study. Infect Drug Resist. 2023;16(null):5185–5195. doi: 10.2147/IDR.S414079
   PubMedGoogle Scholar
• Kumar CK, Sands K, Walsh TR, et al. Global, regional, and national estimates of the impact of a maternal Klebsiella pneumoniae vaccine: a bayesian modeling analysis. PLOS Med. 2023;20(5):e1004239. doi: 10.1371/journal.pmed.1004239
   PubMed Web of Science ®Google Scholar
• Russo TA, Beanan JM, Olson R, et al. Capsular polysaccharide and the O-specific antigen impede antibody binding: a potential obstacle for the successful development of an extraintestinal pathogenic Escherichia coli vaccine. Vaccine. 2009 Jan 14;27(3):388–395. doi: 10.1016/j.vaccine.2008.10.082
   PubMed Web of Science ®Google Scholar
• Wantuch PL, Knoot CJ, Robinson LS, et al. Capsular polysaccharide inhibits vaccine-induced O-antigen antibody binding and function across both classical and hypervirulent K2: O1 strains of Klebsiella pneumoniae. PLOS Pathog. 2023;19(5):e1011367. doi: 10.1371/journal.ppat.1011367
   PubMed Web of Science ®Google Scholar
• Wells TJ, Whitters D, Sevastsyanovich YR, et al. Increased severity of respiratory infections associated with elevated anti-LPS IgG2 which inhibits serum bactericidal killing. J Exp Med. 2014;211(9):1893–1904. doi: 10.1084/jem.20132444
   PubMed Web of Science ®Google Scholar
• Thaden JT, Keller AE, Shire NJ, et al. Pseudomonas aeruginosa bacteremic patients exhibit nonprotective antibody titers against therapeutic antibody targets PcrV and Psl Exopolysaccharide. J Infect Dis. 2015;213(4):640–648. doi: 10.1093/infdis/jiv436
   PubMed Web of Science ®Google Scholar
• Hendriks A, Kerkman PF, Varkila MRJ, et al. Glycan-specific IgM is critical for human immunity to staphylococcus aureus. bioRxiv. 2023; 548956 doi: 10.1242/prelights.35297
   Google Scholar
• Mbaeyi SAB, Catherine H, Duffy J, et al. Meningococcal vaccination: recommendations of the advisory committee on immunization practices, United States, 2020. MMWR Recomm Rep. 2020;69(No. RR–9):1–41. doi: 10.15585/mmwr.rr6909a1
   PubMed Web of Science ®Google Scholar
• Buonsanti C, Balocchi C, Harfouche C, et al. Novel adjuvant Alum-TLR7 significantly potentiates immune response to glycoconjugate vaccines. Sci Rep. 2016 Jul 21;6(1):29063. doi: 10.1038/srep29063
   PubMedGoogle Scholar
• Avci F, Berti F, Dull P, et al. Glycoconjugates: what it would take to master these well-known yet little-understood immunogens for vaccine development. mSphere. 2019 Sep 25;4(5). doi: 10.1128/mSphere.00520-19
   PubMed Web of Science ®Google Scholar
• Pichichero ME. Protein carriers of conjugate vaccines.Hum Vaccines Immunother. 2013;9(12):2505–2523. doi: 10.4161/hv.26109
   PubMed Web of Science ®Google Scholar
• Pöllabauer EM, Petermann R, Ehrlich HJ. The influence of carrier protein on the immunogenicity of simultaneously administered conjugate vaccines in infants. Vaccine. 2009 Mar 10;27(11):1674–1679. doi: 10.1016/j.vaccine.2009.01.005
   PubMed Web of Science ®Google Scholar